Клиническая фармакология Серетида и его место в терапии бронхиальной астмы и хронических обструктивных заболеваний легких
Abstract
Серетид (в США торговая марка Адваир) - новый комбинированный препарат, разработанный компанией GlaxoSmithKline в 1999 г. для лечения больных бронхиальной астмой (БА) и хроническими обструктивны- ми заболеваниями легких (ХОБЛ). Серетид был одобрен FDA (US Food Drug Administration) в августе 2000 г. и вскоре зарегистрирован в Российской Федерации.
About the Authors
А. Цой
Московская медицинская академия им. И.М. Сеченова, г. Москва
Russian Federation
Russian Federation
В. Архипов
Московская медицинская академия им. И.М. Сеченова, г. Москва
Russian Federation
Russian Federation
М. Беда
ГлаксоСмитКляйн, Москва
Russian Federation
Russian Federation
References
1. Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids Am J Respir Crit Care Med 1998; 157: s 51-s 53.
2. Guidelines for the Diagnosis and Management of asthma. Expert panel report, No.2. National institutes of health, Bethesda, MD. (NIP Publication No. 97-4051).
3. Asthma in America web site: http://www.asthmainamerica.com/
4. Asthma Insights & Reality in Europe web site: http://www.asthmaineurope.com/
5. Code of federal regulation & ICH guidelines. Parexel / Barnett International Rose Tree Corporate Center. 2000.
6. Nelson H.S. Advair: Combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. J Allergy Clin Immunol 2001; # 2; Vol. 107:397-416.
7. TRISTAN COPD study. TRISTAN COPD Newsletter; 09.10.2001; p. 1-21.
8. Barnes P.J. Effects of beta2-agonists and steroids on beta2-adrenoreceptor. Eur Respir Rev 1998; 8: 55; 210-215.
9. Barnes P.J., Chung K.F., Page C.P. Inflammatory Mediators of Asthma: An Update. PHARM. REV . 1998; Vol. 50, No. 4; 515-96.
10. Kia Soong Tan, McFarlane L.C., Lipworth B.J. Concomitant Administration of Low-Dose Prednisolone Protects Against In Vivo - Adrenoceptor Subsensitivity Induced by Regular Formoterol. Chest 1998; Vol. 113: # 1; 34-41.
11. Barnes P.J. Effects of beta2-agonists on inflammatory cells. Journal of Allergy and Clinical Immunology. 1999; Vol. 104: # 2: 10-17.
12. Imran Aziz, Hall I.P, McFarlane L.C. et al. ^-Adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. Journal of Allergy and Clinical Immunology. 1998; Vol. 101: # 3: 337-341.
13. Бронхиальная астма, глобальная стратегия. Основные направления лечения профилактики астмы: Всемирная организация здравоохранения, Национальный институт сердце, легкие и кровь. Март 1993. Пульмонология, 1996; Приложение 1. - 165 c.
14. Woolcock A., Lundback B, Ringdal N, Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;.153:1481-8.
15. British Guidelines on Asthma Management. 1995 review and position statement. Thorax 1997;52(suppl 1):.1-21.
16. Carndian asthma consensus report, 1999. CMAJ 1999; 161 [11 Suppl].
17. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ, 20 MAY 2000: Vol 320; 1368-1379.
18. Nials A.T, Ball D.I., Butchers P.R. et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 1994;251:127-35.
19. Chong L.K., Cooper E, Vardey C.J., PeachellP.T. Salmeterol inhibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independent mechanisms. Br J Pharmacol 1998;123:1009-15.
20. Proud D., Reynolds C.J., Lichtenstein L.M., Kagey-Sobotka A., Togias A. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin Exp Allergy 1998;28:868-75.
21. Bissonnette E.Y., Befus D. Anti-inflammatory effect of beta2-agonists: inhibition of TNF-a release from human mast cells. J Allergy Clin Immunol 1997;100:825-31.
22. Butchers P.R., Vardey C.J., Johnson M. Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br J Pharmacol 1991;104:672-6.
23. Dowling R.B., Rayner C.F.J., Rutman A., Jackson A.D., Kanthakumar K., Dewar A. et al. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am J Respir Crit Care Med 1997;155:327-36.
24. Dowling R.B., Johnson M, Cole P.J., Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J 1998;11:86-90.
25. Baraniuk J., Ali M., Brody D, Maniscalco J., Gaumond E, Fitzgerald T. et al. Glucocorticoids induce beta2 -adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997;155:704-10.
26. Eickelberg O., Roth M., Lorx R., Bruce V., Rudiger J., Johnson M. et al. Ligand-independent activation of glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999;274:1005-10.
27. Pang L., Knox A.J. Synergistic inhibition by ^-adrenoceptor agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Respir Cell Mol Biol 2000;23:79-85.
28. Pang L.H., Knox A.J. Inhibition by ^-adrenoceptor agonists and dexa-methasone on TNFalpha stimulated eotaxin release from human airway smooth muscle cells. Respir Med 1999;54(Suppl 3):A6.
29. Mak J.C.W., Nishikawa M., Shirasaki H., Miyayasu K., Barnes P.J. Protective effects of a glucocorticoid on downregulation of pulmonary beta2-adrenergic receptors in vivo. J Clin Invest 1995;96:99-106.
30. Mak J.C.W., Nishikawa M., Barnes P.J. Glucocorticosteroids increase beta-adrenergic receptor transcription in human lung. Am J Physiol 1995;268:L41-6.
31. Anenden V., Egemba G., Kessel B., Johnson M., Costello J. Salmeterol facilitation of fluticasone-induced apoptosis in eosinophils of asthmatics pre- and post-antigen challenge [abstract]. Eur Respir J 1998;12(Suppl 28):157 s.
32. Mosby's Drug Consult. Mosby's GenRx®, 2002, 12th ed. Версия для Internet. Web site: http://www.mdconsult.com/
33. Pulmonary-Allergy Drugs Advisory Committee. Food and Drug Administration. 1995. Questions for the PADAC Meeting, September 25, 1995. U.S. Government Printing Office, Washington, DC.
34. Kavuru M., Melamed J., Gross G., LaForce C., House K., Prillaman B. et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000;105:1108-16.
35. Shapiro G., Lumry W., Wolfe J., Given J., White M.V., Woodring A. et al. Combined salmeterol 50 mcg and fluticasone propionate 250 mcg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000;161:S27-34.
36. Aubier M., Pieters W.R., Schlosser N.J., Steinmetz K-O. Salmeterol/fluticasone propionate (50/500 mcg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999;93:876-84.
37. Nelson H.S., Busse W.W., Kerwin E., Church N., Emmett A., Rickard K. et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000;106:1088-95.
38. Цой А.Н. Применение системы доказательной медицины в лечении бронхиальной астмы // Русский медицинский журнал, 2001, № 1 (том 9), с. 4-8.
39. Finkelstein F.N. Risks of salmeterol [letter]. N Engl J Med, 1994; p. 331-1314.
40. Greening A.P., Wind P.W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet, 1994; #344; p.219-224.
41. Grove A., Lipworth B.J. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet, 1995; #346; p. 201-6.
42. Wilkinson J.R.W., Roberts J.A., BraddingP., Holgate S.T., Howarth P.H. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ, 1992; #305; p. 931-932.
43. Чучалин А.Г. Бронхиальная астма. М., 1997.
44. British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britan. # 38.
45. Postma D.S., Kerstjens H.A.M. Are Inhaled Glucocorticosteroids Effective in Chronic Obstructive Pulmonary Disease? Am J Respir Crit Care Med 1999;160: S66—S71.
46. Global Initiative for Chronic Obstructive Lung Disease. National Heart, Lung, and Blood Institute, NIH and World Health Organization. Executive summary. 2000.
47. Johnson M. в-Adrenoceptor. Am. J. Respir. Crit. Care Med., Volume 158, Number 5, November 1998, S.146-153.
48. Newnham D.M., Grove A., McDevitt D.G., Lipworth B.J. Subsensitivity of bronchodilator and systemic beta2-adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995;50:497-504.
49. Barnes P.J, Woolcock A.J. Difficult asthma. Eur Respir J 1998; 12: 1209-1218.
Review
For citations:
, , . Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2002;(1):90-99. (In Russ.)
Views:
11239
Email this article 